Binding strength, the site recognized and practical molecule properties answer different questions. A useful binder needs evaluation beyond a single affinity value.
A primary comparison of bispecific constructs found different lytic activity despite similar antigen-binding affinity, with epitope geometry contributing to the result. A separate clinical-stage antibody survey measured multiple biophysical properties relevant to developability. Those studies support evaluating recognition, function and molecule behavior separately. Their tested distributions and constructs do not establish a universal selection cutoff or guarantee that a candidate will become an effective drug. Separate measurements distinguish the quantities. For antibodies binding HLA-A2 on cells, the monovalent Fab affinity of one antibody was 1.9 x 10^7 per molar while the avidity of its bivalent F(ab)2 or IgG was 1.3 x 10^9 per molar, an enhancement the authors estimated at 68-fold by simple Scatchard analysis and at a larger value with more realistic models (Ways and Parham, 1983). In mice bearing SK-OV-3 human ovarian carcinoma xenografts, four affinity variants of one anti-HER2 antibody that recognise the same epitope (monovalent KD 270 to 0.56 nmol/L) showed the highest tumour accumulation at moderate affinity; the highest-affinity antibodies stayed in the perivascular space (average penetration 20.4 um versus 84.8 um for the lowest affinity), a conditional result in that model, not an ideal affinity (Rudnick et al., 2011). FDA's Q6B guidance lists physicochemical properties, biological activity, immunochemical properties, purity and impurities as parts of characterisation and ties specifications to the individual product, so no universal cutoff exists.
Shares Format-dependent binder function, Binders as targeting modules, Immune measurements and product evidence.
Shares Binders as targeting modules, Immune measurements and product evidence.
Shares Immune measurements and product evidence, Proteomics & phosphoproteomics.
Shares Immune measurements and product evidence, Proteomics & phosphoproteomics.
Shares Self-similarity and immune-recognition specificity, Immune measurements and product evidence.
Shares Immune measurements and product evidence, Proteomics & phosphoproteomics.
Shares Binders as targeting modules, Epitope.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/